Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Protective Effects of Galium verum L. Extract against Cardiac Ischemia/Reperfusion Injury in Spontaneously Hypertensive Rats.

Bradic J, Zivkovic V, Srejovic I, Jakovljevic V, Petkovic A, Turnic TN, Jeremic J, Jeremic N, Mitrovic S, Sobot T, Ponorac N, Ravic M, Tomovic M.

Oxid Med Cell Longev. 2019 Feb 4;2019:4235405. doi: 10.1155/2019/4235405. eCollection 2019.

2.

The impact of aerobic and anaerobic training regimes on blood pressure in normotensive and hypertensive rats: focus on redox changes.

Jakovljevic B, Nikolic Turnic T, Jeremic N, Jeremic J, Bradic J, Ravic M, Jakovljevic VL, Jelic D, Radovanovic D, Pechanova O, Zivkovic V.

Mol Cell Biochem. 2019 Apr;454(1-2):111-121. doi: 10.1007/s11010-018-3457-y. Epub 2018 Oct 11.

PMID:
30311109
3.

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A.

Blood. 2015 Jun 25;125(26):4024-31. doi: 10.1182/blood-2014-12-614636. Epub 2015 Apr 17.

4.

Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer.

Arends TJ, Lammers RJ, Falke J, van der Heijden AG, Rustighini I, Pozzi R, Ravic M, Eisenhardt A, Vergunst H, Witjes JA.

Clin Genitourin Cancer. 2015 Jun;13(3):204-9.e2. doi: 10.1016/j.clgc.2014.12.010. Epub 2014 Dec 31.

PMID:
25660383
5.

Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer.

Falke J, Lammers RJ, Arentsen HC, Ravic M, Pozzi R, Cornel EB, Vergunst H, de Reijke TM, Witjes JA.

J Urol. 2013 Jun;189(6):2077-82. doi: 10.1016/j.juro.2012.11.150. Epub 2012 Nov 30.

PMID:
23206424
6.

Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.

Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N; ROSE Trial Investigators.

Scand J Gastroenterol. 2006 Oct;41(10):1132-40.

PMID:
16990197
7.

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB.

Clin Cancer Res. 2006 Mar 15;12(6):1776-84.

8.

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH.

Invest New Drugs. 2005 Jun;23(3):225-34.

PMID:
15868378
9.

Phase II study of E7070 in patients with metastatic melanoma.

Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ; EORTC New Drug Development and Melanoma Groups.

Ann Oncol. 2005 Jan;16(1):158-61.

PMID:
15598954
10.
11.

Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.

Dittrich C, Dumez H, Calvert H, Hanauske A, Faber M, Wanders J, Yule M, Ravic M, Fumoleau P.

Clin Cancer Res. 2003 Nov 1;9(14):5195-204.

12.

Intracavitary treatment of malignant gliomas: radioimmunotherapy targeting fibronectin.

Ravic M.

Acta Neurochir Suppl. 2003;88:77-82. No abstract available.

PMID:
14531565
13.

In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.

Bongard HJ, Pluim D, Waardenburg RC, Ravic M, Beijnen JH, Schellens JH.

Anticancer Drugs. 2003 Jul;14(6):405-10.

PMID:
12853880
14.

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.

Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL.

Aliment Pharmacol Ther. 2003 Jun 15;17(12):1507-14.

15.

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).

Terret C, Zanetta S, Roché H, Schellens JH, Faber MN, Wanders J, Ravic M, Droz JP; EORTC Early Clinical Study Group.

Eur J Cancer. 2003 May;39(8):1097-104.

PMID:
12736109
16.
17.

Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

van Kesteren C, Mathôt RA, Raymond E, Armand JP, Fumoleau P, Punt C, Ravic M, Wanders J, Beijnen JH, Schellens JH; Early Clinical Studies Group of the EORTC and NDDO Oncology.

Br J Clin Pharmacol. 2002 Nov;54(5):463-71.

18.

An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.

van sen Bongard HJ, Pluim D, Rosing H, Nan-Offeringa L, Schot M, Ravic M, Schellens JH, Beijnen JH.

Anticancer Drugs. 2002 Sep;13(8):807-14.

PMID:
12394264
19.

Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

Van Kesteren Ch, Mathôt RA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH; Early Clinical Studies Group of the European Organization for Research and Treatment of Cancer.

J Clin Oncol. 2002 Oct 1;20(19):4065-73.

PMID:
12351604
20.

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.

Raymond E, ten Bokkel Huinink WW, Taïeb J, Beijnen JH, Faivre S, Wanders J, Ravic M, Fumoleau P, Armand JP, Schellens JH; European Organization for the Research and Treatment of Cancer Early Clinical Study Group.

J Clin Oncol. 2002 Aug 15;20(16):3508-21.

PMID:
12177112
21.
22.

A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam.

Ravic M, Salas-Herrera I, Johnston A, Turner P, Foley K, Rosenow DE.

Postgrad Med J. 1993 Nov;69(817):865-6.

23.

Renal and general tolerability of repeated doses of nimesulide in normal subjects.

Warrington SJ, Ravic M, Dawnay A.

Drugs. 1993;46 Suppl 1:263-9.

PMID:
7506187
24.

Does bismuth chelate influence lornoxicam absorption?

Ravic M, Johnston A, Turner P, Foley K, Rosenow R.

Hum Exp Toxicol. 1992 Jan;11(1):59-60. No abstract available.

PMID:
1354463
25.

The effect of repeated oral doses of lornoxicam on antipyrine elimination in normal human volunteers.

Ravic M, Johnston A, Turner P, Takacs F, Rosenow DE.

Hum Exp Toxicol. 1991 Sep;10(5):375-7.

PMID:
1683552
26.

A study of the interaction between lornoxicam and warfarin in healthy volunteers.

Ravic M, Johnston A, Turner P, Ferber HP.

Hum Exp Toxicol. 1990 Nov;9(6):413-4. No abstract available.

PMID:
2271233
27.

Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidation.

Warrington SJ, Lewis Y, Dawnay A, Johnston A, Kovacs IB, Lamb E, Ravic M.

Postgrad Med J. 1990;66 Suppl 4:S35-40.

PMID:
2284219
28.

Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.

Ravic M, Johnston A, Turner P.

Postgrad Med J. 1990;66 Suppl 4:S30-4. Review.

PMID:
2126624
29.

Minaprine and imipramine in the treatment of major depressive disorders. A comparative double-blind study.

Bohacek N, Ravic M, Bizière K.

Drugs Exp Clin Res. 1987;13(7):435-42.

PMID:
3308390
30.

A double-blind comparison of minaprine and imipramine in the treatment of depressed patients.

Bohacek N, Ravic M, Bizière K.

J Clin Psychopharmacol. 1986 Oct;6(5):320-1. No abstract available.

PMID:
3771821

Supplemental Content

Support Center